

functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for human factor IX.

19. (Amended) The vector of Claim 18 further comprising a 3' termination sequence which function is Sertoli cells.

20. (Amended) The vector of Claim 18 or 19 further comprising a signal sequence coding for a signal peptide, said signal sequence located downstream from said promoter.

25. (Amended) A Sertoli cell comprising a vector comprising, in the 5' to 3' direction, a promoter which functions in Sertoli cells, operatively linked to a coding sequence for a biological factor wherein said Sertoli cell creates an immunologically privileged site *in vivo*.

26. (Amended) A Sertoli cell comprising a vector comprising in the 5' to 3' direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor and a signal sequence coding for a signal peptide, said signal sequence located downstream from said promoter, wherein said Sertoli cell creates an immunologically privileged site *in vivo*.

Please add the following new Claims:

27. (New) A vector comprising in the 5' to 3' direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for bilirubin UDP-glucuronosyltransferase (B-UGT).

28. (New) A vector comprising in the 5' to 3' direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for any one of the following groups consisting of insulin, IL-2, dopamine, GM-CSF, M-CSF or TNF.

29. (New) A Sertoli cell comprising a vector comprising in the 5' to 3' direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for factor VIII and wherein said Sertoli cell creates an immunologically privileged site *in vivo*.

30. (New) A Sertoli cell comprising a vector comprising in the 5' to 3'

direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for factor IX and wherein said Sertoli cell creates an immunologically privileged site *in vivo*.

31. (New) A Sertoli cell comprising a vector comprising in the 5' to 3' direction a promoter which functions in Sertoli cells operatively linked to a coding sequence for a biological factor wherein said coding sequence is the coding sequence for bilirubin UDP-glucuronosyltransferase (B-UGT) and wherein said Sertoli cell creates an immunologically privileged site *in vivo*.

REMARKS

In the Official Action dated March 22, 2001, Claims 18-26 have been rejected under 35 U.S.C. §112, second paragraph, as allegedly indefinite. Claims 18-20, 25, and 26 have been rejected under 35 U.S.C. §102(b) as allegedly anticipated by Gorman, European